{"id":740851,"date":"2025-04-24T18:32:01","date_gmt":"2025-04-24T18:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=740851"},"modified":"2025-04-24T18:32:01","modified_gmt":"2025-04-24T18:32:01","slug":"lucintel-forecasts-the-global-bladder-cancer-diagnostic-market-to-reach-48-billion-by-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/lucintel-forecasts-the-global-bladder-cancer-diagnostic-market-to-reach-48-billion-by-2030_740851.html","title":{"rendered":"Lucintel Forecasts the Global Bladder Cancer Diagnostic Market to Reach $4.8 billion by 2030"},"content":{"rendered":"
\n
\"Lucintel<\/a><\/div>\n
\n
According to a market report by Lucintel, the future of the global bladder cancer diagnostic market looks promising with opportunities in the hospital, clinic, and cancer center markets. The global bladder cancer diagnostic market is expected to reach an estimated $4.8 billion by 2030 from $3.1 billion in 2024, at a CAGR of 7.8% from 2024 to 2030<\/div>\n<\/div>\n<\/div>\n
According to a market report by Lucintel, the future of the global bladder cancer diagnostic market looks promising with opportunities in the hospital, clinic, and cancer center markets. The global bladder cancer diagnostic market is expected to reach an estimated $4.8 billion by 2030 from $3.1 billion in 2024, at a CAGR of 7.8% from 2024 to 2030<\/div>\n

According to a market report by Lucintel, the future of the global bladder cancer diagnostic market<\/a> looks promising with opportunities in the hospital, clinic, and cancer center markets. The global bladder cancer diagnostic market is expected to reach an estimated $4.8 billion by 2030 from $3.1 billion in 2024, at a CAGR of 7.8% from 2024 to 2030. The major drivers for this market are growing awareness of bladder related diseases, increasing number of geriatric popuation, and rising demand for advanced diagnostic technologies like computed tomography scan and magnetic resonance imaging.<\/p>\n

A more than 150-page report to understand trends, opportunity and forecast in bladder cancer diagnostic market to 2030 by test type (urine lab tests, cystoscopy, biopsy, and imaging test), material (transitional cell bladder cancer, squamous cell bladder cancer, and others), end use industry (hospitals, clinics, cancer center, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World).<\/p>\n

Lucintel forecasts that biopsy is expected to witness highest growth over the forecast period due to its substantial use for effective biopsy technique and advanced imaging and rising preference for transurethral resection of bladder tumor approach.<\/p>\n

Hospital will remain the largest segment due to surge in bladder cancer hospitalizations and substantial availability of healthcare experts in this setting.<\/p>\n

Download sample by clicking on bladder cancer diagnostic market<\/p>\n

North America is expected to witness highest growth over the forecast period due to exisitence of well-established healthcare infrastructure, availability of major biologics companies, and presence of key players in the region.<\/p>\n

Ameritech Diagnostic Reagent, Bristol-Myers Squibb, Eli Lilly, F. Hofmann-La Roche, Glaxosmithkline, Novartis International, Pfizer, Abbott, Endo Pharmaceuticals, Johnson & Johnson are the major suppliers in the bladder cancer diagnostic market.<\/p>\n

This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com To get access of more than 1000 reports at fraction of cost visit Lucintel’s Analytics Dashboard.<\/p>\n

About Lucintel<\/strong><\/p>\n

At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.<\/p>\n

Contact: Roy Almaguer Lucintel Dallas, Texas, USA Email: roy.almaguer@lucintel.com Tel. +1-972-636-5056<\/p>\n

Explore Our Latest Publications<\/strong><\/p>\n

Electrocoating Market <\/strong><\/p>\n

Home Audio Equipment Market <\/strong><\/p>\n

IoT Routers Market <\/strong><\/p>\n

Radiopharmaceutical Theranostics Market <\/strong><\/p>\n

Transcriptomics Technologies Market <\/strong><\/p>\n

Vehicle Scanner Market <\/strong><\/p>\n

E-Motor and Reduction Gearbox Fluid Market <\/strong><\/p>\n

Electric Motorcycle Controller Market <\/strong><\/p>\n

Fuel Filler Assembly Market <\/strong><\/p>\n

Fully Automatic Pulse Shock Absorber Market <\/strong><\/p>\n

Ignition Safety Device (ISD) Market <\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Lucintel<\/a>
Contact Person:<\/strong> Roy Almaguer
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 972.636.5056
Address:<\/strong>8951 Cypress Waters Blvd., Suite 160
City:<\/strong> Dallas
State:<\/strong> TEXAS
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.lucintel.com\/<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

According to a market report by Lucintel, the future of the global bladder cancer diagnostic market looks promising with opportunities in the hospital, clinic, and cancer center markets. The global bladder cancer diagnostic market is expected to reach an estimated … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,417,413,416],"tags":[],"class_list":["post-740851","post","type-post","status-publish","format-standard","hentry","category-Business","category-Marketing-Sales","category-Services","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/740851","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=740851"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/740851\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=740851"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=740851"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=740851"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}